Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 9/20 | 0.34 |
| ▸ | ABL1 | P00519 | 5/20 | 0.33 |
| ▸ | PGR | P06401 | 4/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409233 | 0.81 | CRBN (0.38) | CYP3A4CRBNNR3C1ABL1PGR | |
| SCHEMBL13030225 | 0.79 | CYP3A4 (0.39) | CYP3A4CRBNNR3C1PGRNR3C2 | |
| SCHEMBL482606 | 0.79 | CYP3A4 (0.65) | CYP3A4CRBNFYNTGFBR1ACVR1 | |
| SCHEMBL860118 | 0.79 | CYP3A4 (0.65) | CYP3A4CRBNNR3C1PGRNR3C2 | |
| SCHEMBL847054 | 0.77 | CYP3A4 (0.59) | CYP3A4CRBNARFYNTGFBR1 | |
| SCHEMBL846614 | 0.76 | CYP3A4 (0.66) | CYP3A4CRBNNR3C1PGRNR3C2 | |
| SCHEMBL3403016 | 0.76 | CYP3A4 (0.68) | CYP3A4CRBNNR3C1PGRNR3C2 | |
| SCHEMBL3406008 | 0.76 | CYP3A4 (0.59) | CYP3A4CRBNFYNTGFBR1ACVR1 | |
| SCHEMBL3405437 | 0.76 | CYP3A4 (0.61) | CYP3A4CRBNFYNTGFBR1ACVR1 | |
| SCHEMBL846776 | 0.74 | CYP3A4 (0.61) | CYP3A4CRBNFYNTGFBR1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432554-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-03-28 | — | — | EP | claimed |
| WO-2010133528-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-25 | — | — | WO | claimed |
| US-20100297073-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-11-25 | — | — | US | claimed |
| US-20100297073-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-11-25 | — | — | US | disclosed |
| US-20100297073-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297073-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, EIF2AK2, POLR2B | CYP3A4 302/4885CRBN 1212/4885NR3C1 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.